Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
Wall Street Analysts Forecast Growth
Several analysts have recently commented on the stock. StockNews.com assumed coverage on shares of Corvus Pharmaceuticals in a research report on Friday, July 1st. They set a "sell" rating on the stock. Cantor Fitzgerald cut their target price on shares of Corvus Pharmaceuticals from $8.00 to $4.00 in a research note on Tuesday, August 9th.
Corvus Pharmaceuticals Trading Down 4.3 %
CRVS traded down $0.05 during trading on Friday, hitting $1.10. 365,203 shares of the company traded hands, compared to its average volume of 300,343. The company has a market cap of $51.21 million, a PE ratio of -1.37 and a beta of 0.93. The stock's 50-day simple moving average is $1.00 and its two-hundred day simple moving average is $1.32. Corvus Pharmaceuticals has a 1 year low of $0.75 and a 1 year high of $9.54.